Biocon Pharma Gets USFDA Approval for Generic Heart Failure Drug

Biocon Pharma, a subsidiary of the biotechnology firm Biocon, has secured approval from the US Food and Drug Administration (USFDA) to market its generic version of Sacubitril/Valsartan Tablets. These tablets, available in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, are used to treat chronic heart failure in adults, helping to reduce the risk of death and hospitalization. Additionally, the medication is approved for use in pediatric patients aged one year and older.

This approval marks a significant expansion of Biocon's portfolio, which focuses on complex, vertically integrated drug products.